Arix Bioscience PLC (LON:ARIX), the biotech venture capital company, has noted an announcement from its portfolio company Amplyx Pharmaceuticals regarding a positive result from the Phase 2 clinical trial of its novel antifungal agent, fosmanogepix.
The trial, evaluating the safety and efficacy of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida, met its primary efficacy endpoint, demonstrating a treatment success rate of 80%.
Fosmanogepix was also well tolerated with no treatment-related serious adverse events or discontinuations, said Amplyx. In addition, fosmanogepix demonstrated potent in vitro activity against all Candida isolates obtained from patients in the study, including isolates resistant to other antifungal agents.
“We are very encouraged that fosmanogepix demonstrated a high rate of treatment success, including activity against resistant pathogens, and was well tolerated in patients with invasive Candida infections.
“Importantly, patients were able to easily transition from intravenous to oral formulations during their treatment,” said Michael R. Hodges, MD, chief medical officer of Amplyx.